[Disclosure] Alteogen(196170) to Acquire 859,018 New Shares of Altos Biologics via Subsidiary Merger (No Additional Capital Outflow)

Source Fact: Financial Supervisory Service DART / 2024-11-07

Disclosure Type: Decision to Acquire Shares or Investment Certificates of Other Corporations

💡 3-Second Summary

Alteogen is acquiring KRW 31.1B worth of new shares in its subsidiary Altos Biologics following an intra-group merger with Alteogen Healthcare, which represents a structural consolidation of existing subsidiaries with zero additional cash expenditure.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Issuing Company (Target Entity): Altos Biologics Co., Ltd. (A subsidiary of Alteogen; CEO: Hee-Jung Ji; Core business: Pharmaceutical R&D)
• Details of Acquisition:
  • Number of Shares to Acquire: 859,018 Common Shares (New share acquisition)
  • Acquisition Amount: KRW 31,165,173,040
  • Ratio to Equity Capital: Equivalent to 21.08% of Alteogen’s equity (KRW 147,841,734,336)
  • Ratio to Total Assets: Equivalent to 12.17% of Alteogen’s total assets at the end of the prior fiscal year (KRW 256,099,994,583)
• Total Ownership Post-Acquisition: 5,859,018 shares (Ownership stake: 63.46%)
• Purpose and Method: To enhance operational management efficiency by integrating corporate structures through a merger between subsidiaries (Surviving entity: Altos Biologics Co., Ltd. / Dissolved entity: Alteogen Healthcare Co., Ltd.)
• Key Financial Conditions:
  • As this transaction constitutes an allocation of new shares resulting from an intra-group merger, there is no cash payment or further external capital funding. The transaction will only reflect the combined bookkeeping of subsidiary investments.
  • The acquisition price per share was derived from the issue price of Altos Biologics’ third-party paid-in capital increase conducted within the past 6 months.
• Scheduled Acquisition Date: December 24, 2024
• Summary Financial Status of Target Entity (Altos Biologics, Current Fiscal Year):
  • Total Assets: KRW 63,427M / Total Liabilities: KRW 5,562M / Total Equity: KRW 57,864M
  • Revenue: None ( – ) / Net Loss: KRW -3,339M

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing indicates an internal restructuring and equity adjustment among consolidated units. Unlike external mergers and acquisitions that require new equity investments, this is a short-term governance reorganization event with no immediate impact on Alteogen’s core business fundamental or cash flows. While the headline figures—over KRW 31.1B in transaction value and 21.08% of equity—might seem significant, it is purely an accounting aggregation derived from the merger of two existing subsidiaries under Alteogen’s umbrella.

Since no fresh capital is leaving the parent entity, the impact on consolidated financial statements remains strictly neutral. However, given that the target entity, Altos Biologics, reports zero revenue due to its nature as an R&D unit and has posted annual net losses between KRW 2.5B and KRW 3.3B over the past three years, investors could track whether this administrative merger successfully drives down duplicated overhead costs or enhances operational synergies over the long horizon.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen filed a disclosure regarding an other-corporation share acquisition valued at 21% of its equity capital, but the actual cash outflow for the parent company is exactly ‘zero’. This transaction is a textbook example of corporate streamlining, where one subsidiary, Altos Biologics, absorbs another subsidiary, Alteogen Healthcare. Instead of buying new shares with fresh cash, Alteogen is simply receiving new shares of the surviving subsidiary in exchange for its holding in the dissolved company, leading to a mere reclassification on the balance sheet. As this is an internal cleanup aimed at improving R&D management efficiency, investors should view this as a neutral administrative update rather than a financial strain on the company.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.